Price
No data yet.
Social Signal Score
Revenue
$29.79M+72.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert N. Fried
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 117
- Beta
- 2.09
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 6.89
Financials
Revenue
$29.79M+72.1%Net Income
$963.0KEBITDA
$1.17MFree Cash Flow
$2.68MEPS (diluted)
$0.01Shares Outstanding (diluted)
82.50M+20.9%Operating Expenses
$18.61MCash & Debt
$66.74MReturn of Capital
$2.77MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $129.42M | $17.38M | $0.22 |
| 2024 | $99.60M | $8.55M | $0.10 |
| 2023 | $83.57M | $-4.94M | $-0.07 |
| 2022 | $72.05M | $-16.54M | $-0.24 |
| 2021 | $67.45M | $-27.13M | $-0.40 |
| 2020 | $59.26M | $-19.93M | $-0.33 |
| 2019 | $46.29M | $-32.15M | $-0.56 |
| 2018 | $31.56M | $-33.32M | $-0.61 |
| 2017 | $21.20M | $-11.38M | $-0.26 |
| 2016 | $21.66M | $-2.93M | $-0.08 |
| 2015 | $17.88M | $-2.77M | $-0.08 |
| 2014 | $15.31M | $-5.39M | $-0.15 |
| 2013 | $10.16M | $-4.42M | $-0.13 |
| 2012 | $11.61M | $-11.66M | $-0.39 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.32
- Implied price
- $9.35
- Return from $3.12
- 24.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.65 — today's price is already 32.9% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| -2.0% | 6.0% | 9.7% | 13.0% | 16.0% | 18.7% |
| 3.0% | 11.4% | 15.3% | 18.8% | 21.9% | 24.7% |
| 8.0% | 16.8% | 20.9% | 24.6% | 27.8% | 30.8% |
| 13.0% | 22.2% | 26.5% | 30.3% | 33.7% | 36.8% |
| 18.0% | 27.6% | 32.1% | 36.1% | 39.7% | 42.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsbusinesswire.com·6h ago·Negative
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD-boosting supplement in the United States†, is now available at GNC and Sam's Club retail locations and online at www.gnc.com and www.samsclub.com. “Expand…
View source ↗
Earnings
Tue, Nov 3(in 2 months)
Consensus estimate $0.01 per share
Typical surprise +100.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.01 vs $0.01beat
- Wed, May 6$0.07 vs $0.06beat
- Wed, Mar 4$0.03 vs $0.02beat
- Tue, Nov 4$0.05 vs $0.01beat
- Wed, Aug 6$0.04 vs $0.02beat
- Wed, May 7$0.04 vs $0.02beat
Estimates and results for NAGE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NAGE officers and directors.
- Bought
- $46k
- Sold
- —
2 trades
0 trades
- Pamir Ozanbought
- Pamir Ozanbought
24 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.